PPARG and familial pancreatic carcinoma: This combination of interferon-β and the PPAR-γ agonist troglitazone induced a synergistic effect on the growth inhibition of BxPC-3, a pancreatic cancer cell line, through the counteraction of the interferon-β-induced activation of signal transducer and activator of transcription- (STAT-) 3, the mitogen-activated protein kinase (MAPK), and AKT and the increase in the binding of both STAT-1 related complexes and PPAR-γ with specific DNA responsive elements [59].